Roham Zamanian
Academic Appointments
- Assistant Professor - Med Center Line, Medicine - Pulmonary & Critical Care Medicine
Key Documents
Contact Information
- Academic Offices
Personal Information Email
Professional Overview
Administrative Appointments
- Clinical Director, VMWC Pulmonary Hypertension Database, Vera Moulton Wall Center for Pulmonary Vascular Disease (2006 - present)
- Director, Adult Pulmonary Hypertension Service, Vera Moulton Wall Center for Pulmonary Vascular Disease (2007 - present)
Honors and Awards
- Fellow of the American College of Chest Physicians, American College of Chest Physicians (2008)
- Faculty Teaching Award, Dept of Medicine, Stanford (2007)
- Young Investigator Career Development Award, Entelligence Actelion Young Investigators Program (2006-2007)
- Fellow of the Year, Univ of Califronia, Irvine Medical Center (2002-2003)
- Resident Research Presentation Award, Univ of Calif, Irvine Medical Center - Dept of Medicine (2001)
- Case Presentation Award, ACCP - Chest 2000 (2000)
Professional Education
| Super-Fellowship: | Stanford University, Pulmonary Vascular Disease (2006) |
| Fellowship: | Stanford University, Pulmonary & Critical Care (2005) |
| Fellowship: | UCI Medical Center, Pulmonary & Critical Care (2003) |
| Residency: | UCI Medical Center, Internal Medicine (2002) |
| MD: | University of California, Irvine, Medicine (1999) |
| BS: | University of California, Irvine, Biological Sciences (1994) |
Community and International Work
- Member PHA SLC, US
Internet Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
1. The Utility of S100A4/Mts1 as a Biomarker in Pulmonary Arterial Hypertension (PAH).
2. Prevalence and Treatment of Insulin Resistance in PAH.
3. The Effect of EGF-Receptor Blockade and Elastase Inhibitor on Pulmonary Arteries of Patients with PAH.
4. Characterization of Pulmonary Arteries in Patients with Idiopathic and Secondary PAH by Wedge Angiography.
5. The Optimal Angle for Angiographic Evaluation of the Left Pulmonary Artery in Patients with PAH.
Clinical Trials
- Recruiting Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
- Recruiting FK506 (Tacrolimus) in Pulmonary Arterial Hypertension
- Recruiting A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil), 2 FDA Approved Pulmonary Hypertension Medications
- Recruiting Study of Incidence of Respiratory Tract Adverse Events in Patients Treated With Tyvaso® Compared to Other FDA Approved Pulmonary Arterial Hypertension (PAH) Therapies
Publications
- Functional Class Improvement and Three-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry. Chest. 2013
- Transplantation for Idiopathic Pulmonary Arterial Hypertension: Improvement in the Lung Allocation Score Era. Circulation. 2013
- The intersection of genes and environment: development of pulmonary arterial hypertension in a patient with hereditary hemorrhagic telangiectasia and stimulant exposure. Chest. 2012; (6): 1598-600
- Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011; (6): 692-9
- Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011; (17): 1677; author reply 1678
- Incidence, correlates, and consequences of acute kidney injury in patients with pulmonary arterial hypertension hospitalized with acute right-side heart failure. J Card Fail. 2011; (7): 533-9
Help
Trial Administration